1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

05 Apr 2024
Admin
News Article

EnteroBiotix Starts Phase 2 Study of EBX-102-02

EnteroBiotix begins phase 2 study of EBX-102-02 in patients with irritable bowel syndrome

Overview

EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced that the first patient has been dosed in a multi-centre randomised double-blind placebo controlled clinical trial designed to evaluate EBX-102-02 for the treatment of irritable bowel syndrome (IBS).

TrIuMPH Trial

The phase 2 study, named ‘TrIuMPH’ (treating IBS with an intestinal microbiota product for health) will initially enrol 60 patients with IBS and constipation across sites in the United Kingdom.
The primary objective of the study is to assess the safety and tolerability of EBX-102-02.
Secondary and exploratory endpoints relate to assessing preliminary signals of efficacy of EBX-102-02 and potential biomarkers over a six-week period.
The trial will be delivered in partnership with the Functional Gut Clinic, a leading IBS diagnosis and treatment centre.
EBX-102-02 utilises the company’s proprietary AMPLA technology and is manufactured from its GMP-certified manufacturing facilities in Scotland.

EBX-102-02

EBX-102-02 is a next-generation, full-spectrum drug candidate that contains highly diverse microbial ecosystems and key functional groups that restore and fortify the microbiome.
EBX-102-02 is presented as an easy to take capsule containing off-white colour odourless powder.

Words from CEO: EnteroBiotix

Dr James McIlroy, CEO of EnteroBiotix, said: “We are excited to have achieved this important milestone in our quest to alleviate the suffering caused by IBS. We believe that EBX-102-02 has the potential to be transformational for the IBS patient community and for the field of microbiome therapeutics. We look forward to working in collaboration with our partners to take us closer to realising our vision of tackling unmet clinical needs with best-in-class full-spectrum microbiome medicines.”

Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a chronic relapsing functional GI disorder, with patients experiencing a range of symptoms, such as chronic abdominal pain, cramping, bloating and change in bowel movements – which may include constipation, diarrhoea, or both.
It is estimated that up to 1 in 8 people suffer from IBS type symptoms, and there is approximately an equal split between patients experiencing predominantly constipation (IBS-C) versus diarrhoea (IBS-D).
IBS has a very significant healthcare and economic burden.

About EnteroBiotix

EnteroBiotix is a clinical-stage biopharmaceutical company developing best-in-class full-spectrum microbial therapeutics for patients with serious unmet medical needs.

Functional Gut Clinic

The Functional Gut Clinic (FGC) is the UK’s leading independent provider of gastrointestinal physiology testing and diagnostics.
FGC provides both private and NHS services around the UK and are the only independent GI physiology clinic to have IQIPS/UKAS and CQC accreditation.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!